Boston Scientific (NYSE: BSX) reported Q3 EPS of $0.35, $0.01 better than the analyst estimate of $0.34. Revenue for the quarter came in at $2.39 billion versus the consensus estimate of $2.4 billion.

GUIDANCE:

Boston Scientific sees FY2018 EPS of $1.38-$1.40, versus the consensus of $1.40. Boston Scientific sees FY2018 revenue of $9.787-9.827 billion, versus the consensus of $9.85 billion.

For earnings history and earnings-related data on Boston Scientific (BSX) click here.